✦ LIBER ✦

799 EFFICACY AND SAFETY OF TRIPLE-THERAPY WITH PEGINTERFERON-RIBAVIRIN, AND BOCEPREVIR AS COMPASSIONATE-USE IN SPANISH PATIENTS WITH HEPATITIS C GENOTYPE 1 WITH SEVERE FIBROSIS: INTERIM-ANALYSIS AT 12 WEEKS

✍ Scribed by Calleja, J.L.; Pascasio, J.M.; Ruiz-Antoran, B.; Larrubia, J.R.; Gea, F.; de la Revilla, J.; Forns, X.; Barcena, R.; Romero-Gomez, M.; Crespo, J.; Solá, R.; Fernández, C.; Fernández, I.; Buti, M.

Book ID: 123444654
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 129 KB
Volume: 58
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(13)60801-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and efficacy of triple therapy wi

Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis

✍ Calleja, Jose L.; Pascasio, Juan M.; Ruiz-Antorán, Belén; Gea, Francisco; Bárcen 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 427 KB

Sa1051 Boceprevir Based Triple Therapy i

Sa1051 Boceprevir Based Triple Therapy in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) Under Real Life Conditions in Treatment NaïVE Patients Infected With Chronic Hepatitis C, Genotype 1: An Interim Analysis At Week 12 After Start of Treatment

✍ Moog, Gero; Mauss, Stefan; Hueppe, Dietrich; Spengler, Ulrich; Schott, Eckart; E 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 646 KB

14 EFFICACY AND SAFETY OF WEIGHT-BASED R

14 EFFICACY AND SAFETY OF WEIGHT-BASED REGIMENS OF TARIBAVIRIN OR RIBAVIRIN, GIVEN WITH PEGINTERFERON ALFA-2B, AT 12 WEEKS AFTER TREATMENT (SVR12) IN NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC-HEPATITIS C

✍ F. Poordad; E. Lawitz; R. Pozza; M. Shiffman; B. Bacon; E. Godofsky; D. Halliman 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

601 EFFICACY AND SAFETY OF PEGINTERFERON

601 EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A 360 μG/WEEK IN COMBINATION WITH RIBAVIRIN IN HEPATITIS C GENOTYPE 1 PATIENTS WITH CIRRHOSIS: ANALYSIS FROM THE CHARIOT STUDY

✍ W.S.C. Cheng; S. Roberts; M. Weltman; D.H.G. Crawford; W. Sievert; G. McCaughan; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Efficacy and safety of telaprevir (TVR)

Efficacy and safety of telaprevir (TVR) triple therapy in a ‘real-life’ cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment

✍ Werner, C. R.; Franz, C.; Egetemeyr, D. P.; Janke-Maier, P.; Malek, N. P.; Lauer 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB

187 Efficacy and safety of 22 weeks of m

187 Efficacy and safety of 22 weeks of maintenance therapy with peginterferon alfa-2A (40KD) (PEGASYS™) alone versus peginterferon alfa-2A (40KD) plus ribavirin(COPEGUS™) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of peginterferon alfa-2A (40KD) plus ribavirin: an open, multicenter, randomized trial

✍ Jean-Pierre Bronowicki; Denis Ouzan; Arnaud Tzanck; Tarik Asselah; Herve Desmora 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB